Abstract: An aliphatic epoxy-terminated polysulfide polymer has the formula R?—CHOH—CH2-S—R—(Sy-R)t-S—CH2-CHOH—R? and is formed by a process, where each R is independently chosen from branched alkanediyl or branched arenediyl groups and groups with the structure —(CH2)a-O—(CH2)b-O—(CH2)c- and about 0 to about 20% of the number of R-groups are branched alkanediyl or branched arenediyl groups and about 80 to about 100% of the number of R-groups have the structure —(CH2)a-O—(CH2)b-O—(CH2)c-, where t is from about 1 to about 60, y is an average value of from about 1.0 to about 2.5, b is an integer value of from about 1 to about 8, and a and c are independently integers from about 1 to about 10, and where each R? is independently a particular radical where, m, n, o, p, q and r independently have a value of from about 1 to about 10.

Abstract: Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

Abstract: A diagnostically useful carrier includes (a) a peptide including the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, and (b) a somatic lysate of Toxocara canis larvae. Further, a kit, use, methods, and compositions that include the diagnostically useful carrier are disclosed.

Abstract: Process for the production of a liquid mercapto-terminated polythioethersulfide comprising the step of reacting, at a temperature in the range 0-100° C. and in the presence of a catalyst: at least one compound selected from the group consisting of (i) dimercapto-dioxa-alkanes (DMDAs) and (ii) glycol di(mercapto carboxylic acid ester)s (GDMEs), at least one dimercapto-dialkyl sulfide (DMDS) at least one di-epoxide, and optionally at least one branching agent selected from compounds having at least three terminal groups selected from epoxy and mercapto groups, wherein the molar ratio (DMDA+GDME)/DMDS is in the range 1.1-4.0.

Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.

Abstract: Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

Abstract: A polypeptide contains laminin beta-4 and a carrier contains the polypeptide. An antibody, preferably autoantibody, is against laminin beta-4. Furthermore, use of the polypeptide, carrier or autoantibody for the diagnosis of a disease, and a method with the step of detecting an autoantibody against laminin beta-4 in a sample are described.

Abstract: Process for the production of a liquid mercapto-terminated polythioethersulfide comprising the step of reacting, at a temperature in the range 0-100° C. and in the presence of a catalyst: at least one compound selected from the group consisting of (i) dimercapto-dioxa-alkanes (DMDAs) and (ii) glycol di(mercapto carboxylic acid ester)s (GDMEs), at least one dimercapto-dialkyl sulfide (DMDS) at least one di-epoxide, and optionally at least one branching agent selected from compounds having at least three terminal groups selected from epoxy and mercapto groups, wherein the molar ratio (DMDA+GDME)/DMDS is in the range 1.1-4.0.

Abstract: An aliphatic epoxy-terminated polysulfide polymer has the formula R?—CHOH—CH2-S—R—(Sy-R)t-S—CH2-CHOH—R? and is formed by a process, where each R is independently chosen from branched alkanediyl or branched arenediyl groups and groups with the structure —(CH2)a-O—(CH2)b-O—(CH2)c- and about 0 to about 20% of the number of R-groups are branched alkanediyl or branched arenediyl groups and about 80 to about 100% of the number of R-groups have the structure —(CH2)a-O—(CH2)b-O—(CH2)c-, where t is from about 1 to about 60, y is an average value of from about 1.0 to about 2.5, b is an integer value of from about 1 to about 8, and a and c are independently integers from about 1 to about 10, and where each R? is independently a particular radical where, m, n, o, p, q and r independently have a value of from about 1 to about 10.

Abstract: The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.

Abstract: A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.

Abstract: A diagnostically useful carrier includes (a) a peptide including the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, and (b) a somatic lysate of Toxocara canis larvae. Further, a kit, use, methods, and compositions that include the diagnostically useful carrier are disclosed.

Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.

Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.

Abstract: A method is useful for diagnosing AIG, which includes the step of detecting whether autoantibodies against the beta-subunit of the gastric H+/K+-ATPase are present or not in a sample comprising antibodies. The method utilizes a diagnostically useful carrier that contains a solid phase on which an agent for the specific capture of the autoantibody is immobilized. Furthermore, the diagnostically useful carrier includes a solid phase on which an agent for the specific capture of an autoantibody against the beta-subunit of the gastric H+/K+-ATPase is immobilized.

Abstract: A polypeptide contains laminin beta-4 and a carrier contains the polypeptide. An antibody, preferably autoantibody, is against laminin beta-4. Furthermore, use of the polypeptide, carrier or autoantibody for the diagnosis of a disease, and a method with the step of detecting an autoantibody against laminin beta-4 in a sample are described.

Abstract: A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.

Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient and also antibody binding to RGS8, a method for diagnosing a disease comprising the step detecting in a sample from a patient the level or activity of RGS8, a polypeptide comprising RGS8 or a variant thereof, a use of set polypeptide for the diagnosis of a disease, an antibody binding to RGS8, a use of the antibody for the diagnosis of the disease, a method for isolating an autoantibody binding to RGS8, a pharmaceutical composition or medical device comprising the polypeptide according to the present invention, a kit for the diagnosis of a disease comprising the polypeptide or the medical device according to the present invention and a use of the polypeptide, the antibody or the antibody for the manufacture of a kit or medical device.

Abstract: A personal hygiene device, in particular a toothbrush, has a handle, a treatment head mounted for relative movement with respect to the handle against a spring force when a treatment force is applied in at least one direction onto the treatment head, a treatment-force-measurement unit for determining the applied treatment force comprising an electrically powered coil, a coil core element, and a control circuit for determining a parameter indicative of the inductance of the coil, wherein the coil core element is arranged to be moved with respect to the coil when the treatment head is moved.

Abstract: The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.